Pulmonary macrophage transplantation (PMT) is a developing therapy aimed at treating hereditary pulmonary alveolar proteinosis (hPAP) by using gene-corrected macrophages (mGM-RαMϕs).
A toxicology study on mice showed that PMT was safe and well tolerated, with no significant adverse effects, including no uncontrolled cell growth or lung problems.
Results indicated that PMT effectively reduced lung disease severity in mice while establishing a substantial safety margin.